Glioblastoma Clinical Trials in San Francisco, California

12 studies are recruiting for glioblastoma in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

   The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the bloo…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sutter Health - California Pacific Medical Center, San Francisco, California

   Locations

   56 in total

   Run by

   CarThera

   See if you can join NCT05902169 on ClinicalTrials.gov

2. EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

   This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Gliobla…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California, San Francisco, California

   Locations

   102 in total

   Run by

   NovoCure GmbH

   See if you can join NCT06556563 on ClinicalTrials.gov

3. Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

   This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patien…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Hideho Okada, MD, PhD

   See if you can join NCT06186401 on ClinicalTrials.gov

4. A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

   Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnose…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   63 in total

   Run by

   Global Coalition for Adaptive Research

   See if you can join NCT03970447 on ClinicalTrials.gov

5. ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

   This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recently discovered compo…

   Stage

   Phase 1

   Ages

   2 to 21

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   7 in total

   Run by

   Sabine Mueller, MD, PhD

   See if you can join NCT04732065 on ClinicalTrials.gov

6. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, San Francisco, California

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

7. The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

   Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molec…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   8 in total

   Run by

   Jasper Gerritsen

   See if you can join NCT06283927 on ClinicalTrials.gov

8. The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

   A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent results suggest that resection of the non-contrast-enhancing (NCE) part might yield even better survival outcomes (supramaximal resection, SMR). T…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   University of California, San Francisco (UCSF), San Francisco, California

   Locations

   8 in total

   Run by

   Jasper Gerritsen

   See if you can join NCT06118723 on ClinicalTrials.gov

9. The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

   Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous ev…

   Stage

   Not phased

   Ages

   Up to 90

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   8 in total

   Run by

   Erasmus Medical Center

   See if you can join NCT06273176 on ClinicalTrials.gov

10. The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

    There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internation…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06146725 on ClinicalTrials.gov

11. The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

    There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This stu…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Jasper Gerritsen

    See if you can join NCT06146738 on ClinicalTrials.gov

12. The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections

    The study is designed as an international, multicenter prospective cohort study. Patients with presumed glioblastoma (GBM) in- or near eloquent areas on diagnostic MRI will be selected by neurosurgeons. Patients will be treated following one of three study arms: 1) a craniotomy where the resection …

    Stage

    Not phased

    Ages

    18 to 90

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    8 in total

    Run by

    Erasmus Medical Center

    See if you can join NCT04708171 on ClinicalTrials.gov